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ABSTRACT 
 
Our study investigated DNA vaccines expressing mature dengue virus (DENV) virus-
like particles (VLPs) and developed serological tests to distinguish dengue and Zika. 
We showed that human-codon optimized DNA vaccines improved the expression 
and production of VLPs in vitro compared with non-codon optimized DNA vaccines. 
Human-codon optimized DNA vaccine expressing mature VLPs induced similar level 
of anti-DENV and neutralizing antibodies compared with that expressing mixed 
VLPs. Secondly, we found that DNA-prime and inactivated virion-boost regimens 
improved the immunogenicity in mice compared with DNA vaccine alone. Future 
challenge experiments are needed to show the protective effect of these vaccine 
candidates. Thirdly, we demonstrated that combination of three enzyme-linked 
immunosorbent assays based on non-structural protein 1 can distinguish DENV and 
Zika virus infections with high specificity and sensitivity. In light of the cross-reactivity 
of current serological tests, our findings have implications for serodiagnosis between 
DENV and Zika virus or other flaviviral infections.   
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Flaviviruses 
 
     Flaviviruses are members of the Flaviviridae family and can be transmitted by 
arthropod vectors (Pierson and Diamond 2013). Several members of the flaviviruses 
are known to cause extensive morbidity and mortality globally and have become 
important to public health problems (Gubler 2012). These include encephalitic 
viruses such as Japanese Encephalitis Virus (JEV), West Nile Virus (WNV), Murray 
Valley Encephalitis Virus (MVEV), and St. Louis Encephalitis Virus (SLEV).  Other 
flaviviruses such as Yellow Fever Virus (YFV) and Dengue Virus (DENV) can cause 
hemorrhagic fever (Pierson and Diamond 2013). The recently emerging Zika Virus 
(ZIKV) can cause neurological complications and birth defects such as microcephaly 
(Weaver, Costa et al. 2016). 
 
Dengue virus 
 
     DENV is one of the most important vector-borne viral diseases in humans. 
Infection with any of the four DENV serotypes, DENV1, DENV2, DENV3, and 
DENV4 can cause a wide spectrum of disease (Guzman, Halstead et al. 2010, 
Gubler 2012). Inadequate sewage and waste management following urban growth in 
dengue endemic regions combined with the lack of effort to control the mosquito 
vector allowed epidemic dengue to expand globally (Gubler 2012). The amino acid 
sequence homology among the four serotypes ranges from 63% to 77% 
(Lindenbach, Murray et al. 2013). Co-circulation of multiple DENV serotypes has 
been reported in many endemic countries (Pierson and Diamond 2013).  
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Genome 
 
     DENV is a single-stranded, positive-sense RNA virus with a genome 
approximately 10.6 kb in length that contains a single open reading frame (ORF) 
flanked by 5’ and 3’ noncoding regions (NCR) encoding a polyprotein precursor 
(Lindenbach, Murray et al. 2013). This polyprotein is then cleaved by viral and 
cellular proteases into three structural proteins: the capsid (C), precursor membrane 
(prM), and envelope (E) protein as well as seven non-structural (NS) proteins: NS1, 
NS2A, NS2B, NS3, NS4A, NS4B, and NS5 (Murphy and Whitehead 2011).  
 
Replication cycle 
 
     The DENV enters target host cells such as dendritic cells through clathrin-
mediated endocytosis.  Several cell surface receptors have been characterized to 
interact with DENV particles upon viral entry. Dendritic cell-specific intracellular 
adhesion molecule-3-grabbing non-integrins (DC-SIGN) for example, acts as an 
attachment factor for dengue virus. Following endocytosis, the low pH of the 
endosome induces the conformational changes of the viral E protein and allows the 
fusion between virus and the host cell membrane, releasing the viral RNA from the 
endosome into the cell cytoplasm (Perera, Khaliq et al. 2008, Lindenbach, Murray et 
al. 2013, Guzman and Harris 2015). Translation of the genome then occurs in the 
endoplasmic reticulum (ER) followed by cleavage into three structural proteins and 
seven NS proteins. The virus then undergoes RNA replication in the invaginated 
membrane vesicles derived from ER (Guzman and Harris 2015). Virion assembly 
occurs on the ER membranes, close to the viral RNA replication site. Immature 
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virions, containing prM and E proteins on the surface, bud into the lumen of the ER 
and are transported through the secretary pathway. The virions mature as they go 
through the trans-Golgi network (TGN), where the low pH environment allows the 
cellular serine protease furin to cleave prM into pr peptide and membrane (M) 
protein. This results in the production of mature virions which contain M and E 
proteins on the surface (Perera, Khaliq et al. 2008). However, studies have shown 
that this cleavage is incomplete in DENV and several other flaviviruses, resulting in 
culture supernatants that consist of a mixed population of mature, immature, and 
partially immature virions (Junjhon, Edwards et al. 2010, Plevka, Battisti et al. 2011). 
 
DENV virion 
 
     The DENV virion is spherical and enveloped with a lipid bilayer consisting of 
prM/M and E proteins present on the surface. Inside the envelope, there is a 
nucleocapsid consisting of C protein and RNA genome. Based on several cryo-
electron microscopic (cryo-EM) studies (Kuhn, Zhang et al. 2002, Zhang, Chipman et 
al. 2003, Zhang, Corver et al. 2003, Yu, Zhang et al. 2008), mature virions have a 
smooth surface approximately 50 nm in diameter consisting of 90 E protein dimers, 
whereas immature virions have a spiky surface with approximately 60 nm in 
diameter and consists of 60 trimeric prM-E heterodimers (Perera, Khaliq et al. 2008). 
 
E protein 
 
     The E glycoprotein on the surface of the virion is a major protein that mediates 
binding and fusion activities during virus infection and acts as a major target for 
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neutralizing (NT) antibodies (Abs). X-ray crystallography studies have shown that the 
N-terminal ectodomain of the E protein contains three domains: domain I (DI) which 
is located in the center, domain II (DII) which contains a fusion loop (FL) at the tip 
that is involved in membrane fusion, and domain III (DIII) which is involved in 
receptor binding (Modis, Ogata et al. 2003, Modis, Ogata et al. 2004). 
     During the maturation process of the immature virions, the prM and E proteins on 
the virion undergo a conformational change due to the low pH environment in the 
TGN, where the immature spiky particles become smooth, exposing the prM 
cleavage site. This site is recognized by the cellular serine protease furin, which then 
cleaves the pr peptide from the prM protein (Perera, Khaliq et al. 2008, Yu, Zhang et 
al. 2008), thus disrupting the trimer which gives the immature particles their 
characteristic spiky image. The E protein is rearranged to form a dimer and lays flat 
against the surface in the characteristic herringbone pattern seen on smooth, mature 
particles (Perera, Khaliq et al. 2008).  
 
Epidemiology 
 
     The dengue virus causes a significant burden on both global public health and the 
economy with more than 100 countries endemic with dengue (Gubler 2012, Bhatt, 
Gething et al. 2013, WHO 2017). One report estimates that there are approximately 
390 million infections per year, with about 500,000 of these cases resulting in 
dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) (Bhatt, 
Gething et al. 2013, WHO 2017). In addition to health concerns, reports show that 
264 disability-adjusted life years (DALYs) per million population are lost due to 
infection with DENV (WHO 2015). These numbers however are most likely much 
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lower than the actual numbers because many cases are underreported or 
misdiagnosed (Suaya, Shepard et al. 2009). 
 
Vectors 
 
     DENV is transmitted by two species of mosquitoes. Aedes aegypti is the 
predominant vector for DENV, although Aedes albopictus is also able to transmit the 
virus. A. albopictus was initially found as a secondary vector for DENV in Asia but 
has since spread to North America and Europe where its distribution now largely 
overlaps with that of A. aegypti (WHO 2015, Lessler, Chaisson et al. 2016).  
 
Clinical Features 
 
     An estimated three billion humans are at risk of infection with dengue globally.  
The majority if DENV infections are asymptomatic or show only mild symptoms.  
However, of the approximate 390 million infections per year, 25% of these 
individuals present with apparent infections (Bhatt, Gething et al. 2013) with an 
incubation period that can range from 3 to 14 days, but is generally 4 to 7 days 
(Whitehead, Blaney et al. 2007). Most of the symptomatic cases present as dengue 
fever (DF), which includes mild febrile illness, rash, myalgia, arthralgia, headache, 
and retro-orbital pain.  A smaller percentage of cases (about 5-10%) may develop 
more severe forms known as DHF and DSS, which are associated with acute 
vascular permeability which results in capillary leakage, thrombocytopenia, and 
hemorrhage (Guzman, Halstead et al. 2010, Peeling, Artsob et al. 2010). The loss of 
plasma fluids is the main contributing factor to the severity of the disease and may 
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ultimately lead to a life-threatening shock. Secondary infection with a heterologous 
serotype has been shown to cause DHF and DSS more frequently compared to a 
primary infection (Halstead 1988).  
 
Immune Response 
 
     The adaptive immune response plays a major role in clearing the virus and 
providing protection from re-infection, but is also believed to be the main player in 
the development of severe disease seen in patients with DHF and DSS (Whitehead, 
Blaney et al. 2007). DENV is able to infect a variety of immune cells including 
monocytes, DCs, and macrophages, and upregulates MHC class I on the surface of 
these cells (Rothman 2011).  
 
DENV Infection and Antibody Response 
 
     Primary infection with DENV confers lifelong protection against and correlates 
with type specific NT Abs against that same serotype.  Following primary DENV 
infection, patients develop an early IgM response which is detected 5 or more days 
after onset of illness, followed by an IgG response which is detected from 10-15 
days. Secondary DENV infection with a heterologous serotype does not provide 
protection and increases the risk of severe disease due to ADE. After a secondary 
infection, IgM appears earlier or in the same time frame as that of primary infection 
but usually at lower titers, compared to IgG which increases rapidly due to its 
presence from the previous infection (Sabin 1952, Halstead 1974, Guzman, Alvarez 
et al. 2007, Imrie, Meeks et al. 2007, Peeling, Artsob et al. 2010).  
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     The Flavivirus genus is comprised of several serocomplexes, including the JEV, 
DENV, YFV, and TBEV serocomplexes (Lindenbach, Murray et al. 2013). Group 
reactive (GR) anti-E Abs are able to recognize members of different serocomplexes, 
complex reactive (CR) recognize members within the same serocomplex, and type 
specific (TS) can recognize a single member (Calisher, Karabatsos et al. 1989). 
Several epitope studies of mouse and human anti-E mAbs have shown that GR 
mAbs primarily recognize the FL of DII while TS and CR mAbs recognize DIII 
residues (Modis, Ogata et al. 2003, Modis, Ogata et al. 2004, Crill, Hughes et al. 
2009, Brien, Austin et al. 2010, Shrestha, Brien et al. 2010, de Alwis, Beltramello et 
al. 2011, de Alwis, Smith et al. 2012, Teoh, Kukkaro et al. 2012, Costin, Zaitseva et 
al. 2013, Tsai, Lai et al. 2013). TS mAbs have also been shown to recognize the 
DI/DII hinge and quaternary interdomain epitope (de Alwis, Smith et al. 2012, Teoh, 
Kukkaro et al. 2012). In general, TS mAbs have greater neutralizing potency in vitro 
than that of CR mAbs, which is greater than that of GR mAbs (Gromowski and 
Barrett 2007, Sukupolvi-Petty, Austin et al. 2007, de Alwis, Smith et al. 2012, Teoh, 
Kukkaro et al. 2012). Thus, eliciting TS potent NT anti-E Abs is the main goal of 
current tetravalent dengue vaccines.  
     Infection with one serotype may generate an immune response against both 
homotypic and heterotypic serotypes. Studies of mAbs have shown that anti-FL and 
anti-prM mAbs cause ADE both in vitro (Huang, Yang et al. 2006, Goncalvez, Engle 
et al. 2007, Beltramello, Williams et al. 2010, Dejnirattisai, Jumnainsong et al. 2010, 
Rodenhuis-Zybert, van der Schaar et al. 2010, Rodenhuis-Zybert, Moesker et al. 
2011) and in vivo (Goncalvez, Engle et al. 2007, Zellweger, Prestwood et al. 2010). 
Studies of polyclonal human sera have reported that anti-E Abs were predominantly 
GR and recognized FL residues in DII (4-63%), which were shown to be cross-
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reactive weakly NT or non-NT, whereas only a minor proportion was TS that 
recognize DIII (1-8%), I/II hinge or quaternary epitopes and are potent NT Abs (Lai, 
Tsai et al. 2008, Crill, Hughes et al. 2009, Wahala, Kraus et al. 2009, Lai, Williams et 
al. 2013, Gallichotte, Widman et al. 2015, Nivarthi, Kose et al. 2017). 
 
Antibody-Dependent Enhancement (ADE) 
 
     Individuals with a secondary infection have an increased risk of developing 
severe clinical outcomes such as DHF and DSS (Sangkawibha, Rojanasuphot et al. 
1984, Burke, Nisalak et al. 1988, Guzman, Kouri et al. 1990) which is believed to be 
due to ADE (Halstead and O'Rourke 1977, Halstead 1988). ADE is thought to occur 
when a heterotypic weakly non-NT Ab from a previous DENV infection binds to the 
virus during a subsequent infection but is unable to neutralize the virus (Burke, 
Nisalak et al. 1988, Guzman, Kouri et al. 2000). The newly formed Ab-virus complex 
binds to Fc gamma receptors on monocytes, resulting in an increase in DENV entry 
into cells, replication and virus load and thus causing more severe disease outcomes 
(Murgue, Roche et al. 2000, Vaughn, Green et al. 2000). 
  
Vaccines  
 
     Current strategies for a tetravalent vaccine aim to include all four serotypes as 
immunogens in order to provide full protection and prevent ADE and the severe 
diseases that are associated with it (Whitehead, Blaney et al. 2007, Murphy and 
Whitehead 2011). The ideal DENV vaccine should be free of reactogenicity, induce a 
level of protection that is seen during natural infection, avoid ADE, provide lifelong 
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protection against all four serotypes, and be safe in children and adults (Whitehead, 
Blaney et al. 2007, Guzman and Harris 2015). Development of DENV vaccines have 
been challenging due to the possibility of triggering ADE, difficulty in eliciting 
comparable levels of NT Abs against all four serotypes, conferring life-long 
protection, the lack of an animal model that is able to mimic clinical symptoms seen 
in humans, and the lack of well-defined immune correlates of protection (Guzman 
and Harris 2015).  
     Current DENV vaccine candidates include live-attenuated, recombinant protein, 
DNA, inactivated, virus-like particle (VLP), and virus vector vaccines (Guzman and 
Harris 2015). Dengvaxia (CYD-TDV) from Sanofi Pasteur is a chimeric live-
attenuated vaccine that uses a recombinant infectious cDNA clone of the yellow 
fever 17D vaccine strain as a backbone and substitutes the prM and E genes with 
those of each four DENV serotypes (Guirakhoo, Weltzin et al. 2000, Guirakhoo, 
Pugachev et al. 2004, Villar, Rivera-Medina et al. 2013). Although Dengvaxia has 
been licensed in several dengue-endemic countries (Pang 2016), phase II and 
phase III clinical trials have shown varying efficacies between the four serotypes and 
only moderate overall efficacy (30-60%) despite the presence of NT Abs 
(Sabchareon, Wallace et al. 2012, Capeding, Tran et al. 2014, Villar, Dayan et al. 
2015). Results from the phase III clinical trials of Dengvaxia showed that the vaccine 
efficacy was lower in individuals who were seronegative than those who were 
seropositive, with higher rates of hospitalizations in the vaccinated seronegative 
individuals, suggesting that the vaccine was aiding in the increase of non-NT 
infection-enhancing Abs (Capeding, Tran et al. 2014, Hadinegoro, Arredondo-Garcia 
et al. 2015, Villar, Dayan et al. 2015, Aguiar, Stollenwerk et al. 2016). This event was 
most notable amongst young children. Due to the increased risk of developing 
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severe dengue in the 2-5 year age group, the WHO Strategic Advisory Group of 
Experts (SAGE) has recommended that the vaccine not be administered to children 
under 9 years of age (Capeding, Tran et al. 2014, Villar, Dayan et al. 2015, Pang 
2016).  Thus, there is a need for a better understanding of NT Abs and the immune 
correlates of protection and a need for a better vaccine. 
     DNA vaccines are also being considered as a candidate for dengue and other 
flavivirus vaccines (Martin, Pierson et al. 2007, Beckett, Tjaden et al. 2011).  Benefits 
of DNA vaccines include ease and flexibility of construction, stability, intracellular 
production of antigen, transient expression, no induction of antivector immunity, 
induction of humoral and cellular immunity, and low occurrence of reactogenicity 
(Martin, Pierson et al. 2007, Danko, Beckett et al. 2011, De Filette, Soehle et al. 
2014).  
 
Zika Virus (ZIKV) 
 
Zika, which was first discovered in 1947, was characterized as causing only a 
mild or inapparent disease similar to dengue (Fauci and Morens 2016). However, 
ZIKV emerged as a major public health concern, first as a large outbreak on Yap 
Island in 2007 with over 70% of the population infected (Duffy, Chen et al. 2009), 
followed by another outbreak in French Polynesia from 2013-2014 infecting 66% of 
the population (Cao-Lormeau, Roche et al. 2014), and finally most recently in Central 
and South America starting in 2015 (WHO 2015, Fauci and Morens 2016, CDC 
2017).  Phylogenetics has shown that ZIKV is closely related to the DENV 
serocomplex (Calisher, Karabatsos et al. 1989, Lessler, Chaisson et al. 2016). The 
global spread of ZIKV starting from DENV endemic regions has raised concerns on 
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its co-circulation with other flaviviruses such as WNV, TBEV, JEV, and YFV (Lessler, 
Chaisson et al. 2016). 
 
Genome 
 
     Like other members of the Flaviviridae family, ZIKV is a positive-sense single-
stranded RNA virus with a genome encoding a single polyprotein which is then 
cleaved by viral and cellular proteases into three structural proteins: the C, prM, and 
E protein as well as seven NS proteins: NS1, NS2A, NS2B, NS3, NS4A, NS4B, and 
NS5 (Song, Qi et al. 2016).  
 
Epidemiology 
 
     Since the first outbreak in 2007 on Yap Island (Lanciotti, Kosoy et al. 2008, Duffy, 
Chen et al. 2009), ZIKV has spread globally, with large outbreaks occurring in Brazil 
and the Americas (WHO 2015, Lessler, Chaisson et al. 2016, Weaver, Costa et al. 
2016).  Imported cases from travelers to endemic regions as well as local cases in 
United States territories have also been reported (CDC 2017). Accurate data on 
global case counts of Zika is currently not available, as Zika was not mandatory to 
report.  Estimates from Brazil range between approximately 500,000 to 1,500,000 
infections (Weaver, Costa et al. 2016). An increase in the number of infants born 
with the microcephaly, a form of congenital brain abnormality, in Brazil suggests its 
possible link to Zika infection (Kleber de Oliveira, Cortez-Escalante et al. 2016, 
Schuler-Faccini, Ribeiro et al. 2016). Although experts were initially reluctant to state 
a causal relationship between Zika and microcephaly, growing evidence from in vitro 
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(Chan, Yip et al. 2016, Onorati, Li et al. 2016, Pawitwar, Dhar et al. 2017), animal 
(Cugola, Fernandes et al. 2016, Li, Saucedo-Cuevas et al. 2016, Manangeeswaran, 
Ireland et al. 2016, Miner, Cao et al. 2016) and clinical studies (Brasil, Pereira et al. , 
Calvet, Aguiar et al. 2016, Driggers, Ho et al. 2016, Mlakar, Korva et al. 2016) have 
shown a strong association and supported a causal relationship (Rasmussen, 
Jamieson et al. 2016). 
 
Vectors 
 
     Like DENV, ZIKV is also transmitted A. aegypti and A. albopictus. Both mosquito 
vectors are found in Asia, parts of North and South America, and Africa where its 
distribution overlaps with both DENV and ZIKV (WHO 2015, Lessler, Chaisson et al. 
2016).  
 
Clinical Features 
 
     After ZIKV infection, majority are inapparent, and only 20% of individuals 
presenting with symptoms that include a slight fever, conjunctivitis, rash, myalgia, 
joint pain, and muscle pain (Pawitwar, Dhar et al. 2017). Due to the non-specific 
nature and similarity of the symptoms to that of the co-circulating DENV, it is difficult 
to diagnose and differentiate between the two flaviviral infections. Infected adults 
may also develop Guillain-Barre Syndrome, as many countries have reported 
increases in the occurrence ranging from two to ten times than that before the ZIKV 
outbreaks (Cao-Lormeau, Blake et al. 2016, Dos Santos, Rodriguez et al. 2016, 
Petersen, Jamieson et al. 2016).  Increasing evidence has also shown the 
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association between infants born with microcephaly from mothers infected with ZIKV 
during their pregnancy (Brasil, Pereira et al. , Mlakar, Korva et al. 2016, Rubin, 
Greene et al. 2016). 
        
Diagnosis 
 
Due to the nonspecific and similar clinical manifestations caused by ZIKV and 
DENV (Simmons , Farrar  et al. 2012, Waggoner, Gresh et al. 2016), these 
flaviviruses can be misdiagnosed for each other. This is especially difficult for ZIKV 
and DENV because of their geographic overlap where co-infections and secondary 
infections are common. 
Current CDC authorized tests for diagnosing a ZIKV infection including the Zika 
E-protein based immunoglobulin M capture enzyme-linked immunoabsorbent assay 
(MAC-ELISA) and Trioplex real-time reverse transcription-polymerase chain reaction 
assay (Oussayef, Pillai et al. 2017). Guidelines for laboratory diagnosis of ZIKV start 
with a two week period after a symptomatic or asymptomatic traveler returns from an 
area with ZIKV activity.  Within this two week period, RT-PCR will be conducted on 
serum, saliva, urine or other body fluids for confirmatory results.  Beyond this 2 week 
window, serum will be tested with the IgM MAC-ELISA.  A test with negative results 
for ZIKV as well as DENV will indicate no recent DENV or ZIKV infection.  However, 
a positive result for any of these two indicates a presumptive flavivirus infection but 
cannot confirm a ZIKV infection and will need to undergo further testing with a 
plaque reduction neutralization test (PRNT). Although a positive PRNT result for 
either DENV or ZIKV will indicate a recent primary infection, a positive for both 
cannot differentiate between the flavivirus infections (CDC 2016). 
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     Difficulty with using the IgM MAC-ELISA may be due to the cross-reactivity 
between DENV and ZIKV E protein. An alternative to this is to use NS1 ELISAs, 
which have been reported to have high sensitivity and specificity (Steinhagen, Probst 
et al. 2016). This ZIKV-NS1 ELISA however does not address the question whether 
serum from secondary DENV infection can cross-react to ZIKV-NS1 and whether it 
can distinguish between primary ZIKV (pZIKV) and ZIKV with previous DENV 
infection (ZIKVwpDENV). 
 
Hypothesis and specific aims  
 
Specific Aim 1. Test if codon-optimized DNA vaccine expressing mature DENV 
virus-like particles (VLPs) induce better antibody responses than that 
expressing mixed VLPs. 
Hypothesis:  DNA vaccines expressing mature DENV particles induce less cross-
reactive anti-FL Abs and no anti-prM Abs, compared with DNA vaccines expressing 
mixed DENV particles. 
Rationale: Anti-FL and anti-prM mAbs are cross-reactive weakly or non-NT and 
cause ADE in vitro and in vivo (Huang, Yang et al. 2006, Goncalvez, Engle et al. 
2007, Dejnirattisai, Jumnainsong et al. 2010, Rodenhuis-Zybert, van der Schaar et 
al. 2010, Rodenhuis-Zybert, Moesker et al. 2011). FL is exposed on immature and 
partially immature particles but poorly exposed on mature DENV particles, and pr is 
exposed on immature and partially immature particles but not on mature DENV 
particles (Kuhn, Zhang et al. 2002, Zhang, Chipman et al. 2003, Zhang, Corver et al. 
2003, Li, Lok et al. 2008).  
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Experimental Plan: Expression and production of VLPs in vitro will be tested by 
Western blot (WB) analysis. Female 6-week-old C57/BL6 mice will be immunized 
intramuscularly (IM) with 3 doses of DNA vaccines expressing mature or mixed 
DENV VLPs of DENV1. Sera will be assayed for binding anti-DENV Abs by ELISA 
and neutralization by foci reduction neutralization test (FRNT) using wild type (WT) 
DENV1 VLPs (Crill, Hughes et al. 2012, Hughes, Crill et al. 2012). 
 
Specific Aim 2. Test if DNA-prime and protein-boost strategy induces stronger 
antibody response than DNA alone. 
Hypothesis:  Heterologous DNA-prime and protein-boost vaccination elicits stronger 
antibody response compared to a DNA-only homologous vaccination strategy 
(Simmons, Porter et al. 2006, De Filette, Soehle et al. 2014). 
Rationale: Although DNA vaccines are able to elicit cell-mediated immune 
responses, most DENV DNA vaccines in previous studies have only shown 
moderate NT Ab titers in mouse and non-human primate models. Several studies 
have shown that the use of a heterologous prime-boost strategy can induce higher 
antibody titers than a homologous vaccine strategy (Simmons, Porter et al. 2006, De 
Filette, Soehle et al. 2014). 
Experimental Plan: Recombinant truncated E protein and inactivated DENV1 virion 
will be generated.  6-week-old female C57/BL6 mice will be immunized IM with 1 
dose of DNA vaccines expressing mature or mixed DENV VLPs of  DENV1, followed 
by two doses of either recombinant E protein or inactivated virion. Sera will be 
assayed for binding anti-DENV Abs by ELISA using wild type (WT), mature (m), or 
immature (Imm) DENV1 VLPs and neutralization by FRNT using WT DENV1 virions 
(Crill, Hughes et al. 2012, Hughes, Crill et al. 2012). 
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Specific Aim 3. To develop and validate a serological test to distinguish DENV 
and ZIKV. 
Hypothesis:  Recombinant NS1 (rNS1) based IgG and IgM ELISA can detect and 
differentiate between anti-NS1 Ab to DENV and ZIKV.  
Rationale: Current IgM ELISA cannot confirm ZIKV infection due to cross-reactivity 
to E protein between ZIKV, DENV, and other flaviviruses (Lai, Tsai et al. 2008, Tsai, 
Durbin et al. 2015, CDC 2016, Oussayef, Pillai et al. 2017). Previous studies have 
shown that anti-NS1 Ab in human sera after DENV infection recognize DENV NS1 
protein but not WNV NS1 protein, suggesting they are not cross-reactive between 
different flaviviral serocomplexes (Lai, Tsai et al. 2008, Tsai, Durbin et al. 2015). 
Another recent study has demonstrated that anti-NS1 mAbs derived from Zika cases 
are mostly not cross-reactive to DENV and vice versa, and polyclonal sera from Zika 
cases without previous dengue can distinguish DENV and ZIKV NS1 (Stettler, 
Beltramello et al. 2016). 
Experimental Plan: Recombinant NS1 protein will be generated for ZIKV, DENV1-2, 
WNV, and YFV. RT-PCR confirmed sera of patients with pZIKV), ZIKVwpDENV and 
secondary DENV (sDENV) infections will be assayed by IgG and IgM ELISA using 
rNS1 proteins. 
 
Significance and Innovation.  
 
Compared with mixed DENV particles, vaccination with mature DENV particles can 
induce NT Abs, less cross-reactive weakly or non-NT Abs and no anti-prM Abs, thus 
reducing the risk of ADE and severe diseases. This represents a novel strategy for 
safe and effective DENV vaccines. 
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Current serological tests to diagnose Zika infections are unable to distinguish pZIKV 
and ZIKVwpDENV. Recent studies have shown that anti-DENV mAbs and polyclonal 
sera can enhance ZIKV infection in vitro through ADE, raising the possibility that 
previous DENV infection may increase the risk and severity of fetal microcephaly 
(Castanha, Braga et al. 2016, Dejnirattisai, Supasa et al. 2016, Priyamvada, Quicke 
et al. 2016, Stettler, Beltramello et al. 2016), further necessitating a serological test 
that can distinguish between pZIKV and ZIKVwpDENV and further our 
understanding of ZIKV pathogenesis and complications during pregnancy. 
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Preparation of VLPs 
 
     HEK293T cells, prepared in a 10-cm culture dish at 5 x 105 cells per dish 1 day 
earlier, were transfected with 10 μg of plasmid DNA using the Lipofectamine 2000 
method (Life Sciences). The plasmid DNA constructs expressed the prM/E proteins 
of DENV1 in the presence or absence of furin to produce mature or immature VLPs, 
respectively. At 48 h post-transfection, culture supernatants were collected, and cells 
were washed with phosphate-buffered saline (PBS) and treated with 1% NP40 lysis 
buffer (100 mM Tris [pH 7.5], 150 mM NaCl, 20 mM EDTA, 1% NP40, 0.5% sodium 
deoxycholate, and protease inhibitors [Roche Diagnostics]), followed by 
centrifugation at 20,000 x g and 4°C for 30 min to obtain cell lysates (Hsieh, Zou et 
al. 2011).  
     Culture supernatants were separated by centrifugation at 1,250 x g and 4°C for 
20 min, filtered through a 0.22-μm-pore-sized membrane (Millipore), layered over a 
20% sucrose buffer, and ultracentrifuged at 65,000 x g and 4°C for 5 h to obtain 
pellets containing VLPs, which were re-suspended in 30 L 1 x PBS buffer (Hsieh, 
Zou et al. 2011).  
 
Western blot analysis 
 
     WB analysis was performed by first adding cell lysates or pellets to 4 x non-
reducing buffer (2% SDS, 0.5 M Tris [pH 6.8], 20% glycerol, 0.001% bromophenol 
blue [final concentrations]) and subjected to 12% polyacrylamide gel electrophoresis 
(PAGE) using an apparatus (Bio Rad) at 80 – 120 V. The gel was then transferred at 
1.3 A for 7 m (BIO-RAD Trans-Blot Turbo Transfer System) to a nitrocellulose 
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membrane (BIO-RAD). After blocking with blocking buffer (4% milk in wash buffer; 
10 mM Tris [pH7.4], 150 mM NaCl, 0.2% Tween-20 [final concentrations]), the 
membrane was incubated at 4oC overnight with primary antibody (anti-E mouse mAb 
at 1:200000; calnexin 1:10000). After washing three times with 1 x PBS at 10 min 
per wash on the following day, the membrane was incubated at room temperature 
(RT) for 1 h with secondary Ab (anti-mouse IgG at 1:10000, Pierce). After washing 
three times at 10 min per wash, the signals were detected by enhanced 
chemiluminescence reagents (Perkin Elmer Life Sciences) (Lai, Tsai et al. 2008, 
Hsieh, Zou et al. 2011). The intensities of mature and immature VLPs were 
compared. 
 
Constructs of DNA vaccine 
 
The prM/E expression plasmids of the D1 serotype (pCB-D1 constructs), were used 
as DNA vaccines (Hu, Hsieh et al. 2007). The prM/E expression plasmids containing 
furin, designated as pCB-F constructs, were generated by inserting IRES-furin-flag 
into the pCB-WT constructs. Human codon optimized prM/E expression plasmids 
were designated as pCB-D1h and pCB-D1hF.  Insertions were verified by the 
patterns of restriction enzyme digestion and sequencing of the entire insert. DNA 
plasmids were amplified using DH5α competent cells and purified using an 
endotoxin-free plasmid DNA Purification Kit (Omega Biotek,Qiagen).  
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Constructs of recombinant E protein 
 
Recombinant E (rE) protein expression plasmids of the four DENV serotypes were 
generated with pMT/Bip-based constructs containing prM and C-terminally truncated 
E for expression in Drosophila S2 cells. Constructs include C-terminal E truncations 
at amino acid residue position 395 (pMT/Bip-D1E80), 400 (pMT/Bip-D1E81, 
pMT/Bip-D2E81, pMT/Bip-D3E81, pMT/Bip-D4E81), 408 (pMT/Bip-D1E82), and 416 
(pMT/Bip-D184). Insertions were verified by the patterns of restriction enzyme 
digestion and sequencing of the entire insert. DNA plasmids were amplified using 
DH5α competent cells and purified using an endotoxin-free plasmid DNA Purification 
Kit (OmegaBiotek, Qiagen).  
 
Expression and purification of rE protein 
 
Drosophila S2 cells were transfected with pMT/Bip-based rE constructs using 
Lipofectamine LTX (Life Sciences) to express rE protein and incubated at 27 oC.  
Stable clones were generated using hygromycin B selection in 10 ml of serum free 
medium, followed by expanding to 1200 ml for purification.  Total volume of 1200 ml 
was purified through a 1 ml immunoaffinity column conjugated with anti-E mAb 4G2 
using the AKTA system (GE).  The purified rE proteins were concentrated into 2-3 ml 
volumes and stored in -80 oC.  Concentrations of proteins were quantified using 
spectrophotometry. 
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Preparation of inactivated DENV for mouse immunization 
 
     Purified inactivated DENV1 viruses were kindly provided by Dr. Wen-Yang Tsai.  
Briefly, HEK293T cells and HEK293T-furin cells, prepared in a 75 mL flask at 7 x 106 
cells per flask, were infected with DENV1 (Hawaii strain) at a multiplicity of infection 
(MOI) of 0.05 to generate mixed (DENV1mixed) and mature (DENV1m) virions, 
respectively. HEK293T cells infected with DENV1 were further treated with NH4Cl to 
obtain immature (DENV1imm) virions. Culture supernatant was harvested when 50% 
cytopathic effect (CPE) was observed and subjected to ultracentrifugation (25,000 
rpm, 5 h at 4oC) to collect virus in the pellets. Purified viruses were inactivated by 
formalin (0.05%, 22 oC water bath, 10 days) (Putnak, Barvir et al. 1996) or H2O2 (3%, 
22-24 oC, 2 h prior to performing mouse immunization) (Amanna, Raue et al. 2012). 
 
Vertebrate Animals 
 
     This study was conducted according to the principles in the NIH Guide for the 
Care and Use of Laboratory Animals. All animal experiment protocol (Wang 12-
1014-5) were approved by the Institutional Animal Care and Use Committees 
(IACUC) at the University of Hawaii at Manoa. Procedures comply with the USDA 
Animal Welfare Act Regulations, American Veterinary Medical Association (AVMA) 
Guidelines for the Euthanasia of Animals: 2013 Edition, and the Guide for the Care 
and Use of Laboratory Animals 8th Edition (2011). 
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Mice immunization schedule 
 
     Mice were obtained from COBRE core facility (kindly provided by Dr. Vivek 
Nerurkar) and were maintained in the animal facility of John A. Burns School of 
Medicine, University of Hawaii at Manoa. Seven week-old female C57BL/6 mice (n = 
5-7/group) were immunized with PBS, pCB-D1, pCB-D1F, pCB-D1h, or pCB-D1hF 
DNA vaccines at 0 week (wk), 3 wk, and 6 wk for the DNA only groups (DDD), or 
with formalin- or H2O2- inactivated D1WT or D1m virion (DVVformalin, DVV H2O2). 
Immunization with DNA was conducted by intramuscular (im) injection with 50 L 
PBS or DNA vaccine (pCB-D1, pCB-D1h 50 µg/µl; pCB-D1F, pCB-D1hF 80 µg/µl) 
injected into the thigh of each mouse. Immunization with inactivated virion was 
conducted by either subcutaneous (sc) or intraperitoneal (ip) injection at 3 wk and 6 
wk (5 µg). Mice were bled submandibularly (sm) at 0 wk, 2 wk, 5 wk, and via 
cardiopuncture (cp) at 10-12 wks. 
 
Mouse Serum Collection 
 
     Whole blood collected from C57/BL6 mice were centrifuged at 2,500 rpm for 5 
min; the supernatants (sera) were collected and then stored in -80oC. Pooled sera of 
mice from each group as well as individual mice sera were tested for ELISA and 
FRNT assay. 
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Preparation of inactivated DENV for ELISA 
 
     Vero cells, prepared in a 75 mL flask at 7 x 106 cells per flask were infected with 
DENV1 (Hawaii strain) at a multiplicity of infection (MOI) of 0.05. Culture supernatant 
was harvested when 50% cytopathic effect (CPE) was observed and subjected to 
ultracentrifugation (25,000 rpm, 5 h at 4oC) to collect virions in the pellets. Virions 
were inactivated by UV (Strategen, 600 V, twice, 5 min). 
 
Three-layer virion ELISA 
 
     Three-layer ELISA was performed on collected sera of PBS and DNA vaccinated 
groups at various time points. 96-well flat-bottom plates were coated with vero-
derived inactivated DENV1 virion or HEK293T-derived DENV1mixed, DENV1m, or 
DENV1imm virions and incubated at 4oC overnight. Blocking buffer (Starting BlockTM, 
Thermo) was added the following day and the plate was incubated at room 
temperature for 1 h, followed by incubation of primary Ab (pooled mice sera or 
individual mice sera with serial dilutions) at 37oC for 2 h and washing four times. 
Incubation of secondary Ab (goat anti-mouse Ab at 1:5000 dilution, or donkey anti-
human Ab at 1:10000 dilution, Jackson Laboratory) was done at 37oC for 1 h, 
followed by washing 6 times. TMB was added and incubated at room temperature for 
15 min. Stop solution (2N H2SO4) was added promptly. OD was measured at a 
wavelength of 450 nm with reference wavelength of 650 nm using an ELISA plate 
reader (BioTek ELx50) (Tsai et al., 2013). O.D. results were analyzed by Graph Pad 
Prism 5.0 and endpoint titers were calculated. 
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Modified Focus Reduction Neutralization Test (FRNT) 
 
     Modified FRNT assays against DENV1 serotype were performed on collected 
pooled and individual sera to test the neutralization potency. Vero cells were seeded 
on a 96-well ELISPOT plate in 10% DMEM one day prior to virus infection and 
incubated at 37oC. Two-fold serial dilutions of each serum were prepared and 
incubated with 50 focus-forming unites (ffu) of DENV1 virus serotype at 37oC for 1 h. 
Virus-serum mixture was inoculated into the Vero cell monolayers and incubated at 
37oC for 90 min with gentle shaking every 15 min during the incubation. After 150 L 
of overlay with 2% FBS DMEM, plates were incubated at 37oC for 70 h. The plates 
were then washed with 200 L of 1 x PBS 3 times, and fixed with 200 L fixation 
buffer (30% methanol/70% acetone) for 20 min in -20 oC. After removing the fixation 
buffer and drying at room temperature for 1 h, 200 L of blocking solution (5% milk in 
1 x PBS) was added and incubated on a shaker at room temperature for 30 min. 
After removing the blocking buffer, primary Ab (human Ab, Palau #8, 1:10,000 
dilution) was added and incubated at 37oC for 1 h. After washing 3 times with 1 x 
PBS, secondary Ab (anti-human Ab, 1:10,000 dilution, 800 nm; DRAQ5 fluorescent 
probe, 1:10,000, 700 nm) was added and incubated at 37oC for 1 h. After washing 3 
times with 1 x PBS, the plate was then washed with ddH2O and dried overnight. 
Plates were read with LI-COR Odyssey and the titers of FRNT50 were determined by 
a nonlinear regression analysis using Graph Pad Prism 5.0. 
 
 
 
 
 45 
Constructs of recombinant NS1 protein 
 
Recombinant NS1 (rNS1) protein expression plasmids of the DENV1 serotype, 
WNV, and ZIKV were generated with pMT/Bip-based constructs (pMT/Bip-D1-NS1, 
pMT/Bip-WNV-NS1, pMT/Bip-ZIKV-NS1) with His-tag at the C-terminus (Integrated 
DNA Technologies) containing codon-optimized NS1 gene (amino acids 1-352) for 
expression in Drosophila S2 cells. Insertions were verified by the patterns of 
restriction enzyme digestion and sequencing of the entire insert. DNA plasmids were 
amplified using DH5α competent cells and purified using an endotoxin-free plasmid 
DNA Purification Kit (OmegaBiotek, Qiagen).  
 
Expression and purification of rNS1 protein 
 
Serum-free adapted drosophila S2 cells (kindly provided by Dr. David Clements at 
the Hawaii Biotech) were co-transfected with pMT/Bip-based rNS1 constructs and 
selection plasmid hygromycin B using Lipofectamine LTX (Life Sciences) to express 
rNS1 and incubated at 27 oC. Total volume of 600 ml was purified through a 1 ml 
His-trap column using the AKTA system (GE). The purified protein were 
concentrated into volumes of 2-3 ml and stored in -80oC. Concentrations of proteins 
were quantified using spectrophotometry. 
 
Three-layer rNS1 ELISA 
 
     Three-layer ELISA was performed on human serum or plasma samples from of 
ZIKV-, DENV1-, and WNV- infected individuals. 96-well ELISA plates were coated 
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with 16 ng/well with ZIKV-NS1, D1-NS1, or WNV-NS1 and incubated at 4oC 
overnight. Blocking buffer (Starting BlockTM, Thermo) was added the following day 
and the plate was incubated at room temperature for 1 h, followed by incubation of 
primary Ab (mouse anti-His at1:5000 dilution, or human sera and plasma at 1:400 
dilution) at 37oC for 2 h and washing four times. Incubation of secondary Ab (goat 
anti-mouse Ab at 1:5000 dilution, or donkey anti-human Ab at 1:10000 dilution, 
Jackson Laboratory) was done at 37oC for 1 h, followed by washing 6 times. TMB 
was added and incubated at room temperature for 15 min. Stop solution (2N H2SO4) 
was added promptly. OD was measured at a wavelength of 450 nm with reference 
wavelength of 650 nm using an ELISA plate reader (BioTek ELx50) (Tsai, Lai et al. 
2013). NS1-IgM ELISA was performed similarly except that each sample was 
incubated with Gullsorb reagent (Meridian Bioscience), an IgG absorbent, for 10 min 
before adding to wells (100 ng NS1 per well) (Paldanius, Bloigu et al. 2003). O.D. 
results were analyzed using GraphPad Prism 6 and endpoint titers were calculated. 
Two-tailed Mann-Whitney test was used to determine the P-value comparing the 
relative OD (rOD) values between two groups.  
 
Clinical samples 
 
     The study of coded serum or plasma samples was approved by Institutional 
Review Boards (IRB) of the University of Hawaii (CHS #17568, CHS#23786). Forty 
convalescent-phase samples from RT-PCR confirmed Zika cases that were DENV-
naïve (n=20) or previously DENV-exposed (n=20), designated as primary ZIKV and 
ZIKV with previous DENV infection panels respectively, were kindly provided by Dr. 
Eva Harris at the University of California Berkeley from the Pediatric Dengue Cohort 
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Study in Managua, Nicaragua between July and September, 2016 (Kuan et al., 
2009). The study was approved by the IRBs of the University of California, Berkeley, 
and Nicaraguan Ministry of Health.  
     Nineteen convalescent-phase samples from patients who presented with 
symptoms compatible with Zika and had detectable anti-DENV IgG antibodies, 
designated as probable ZIKV with previous DENV infection panel, were kindly 
provided by Dr. Carlos Brites at the Federal University of Bahia, Salvador, Brazil 
between November 2015 and May 2016. The study was approved by the IRB of 
Federal University of Bahia.  
     Convalescent-phase or post-convalescent-phase dengue samples were from RT-
PCR confirmed dengue cases including 40 from Kaohsiung, Taiwan between 2001 
and 2009 (Wang et al., 2006),18 from Nicaragua (three cases with sequential 
samples) between 2006 and 2008 (Lai et al., 2013), and 12 from the Big Island, 
Hawaii during the 2015 DENV1 outbreak. Flavivirus-naïve samples (n=12) were from 
previous studies (Lai et al., 2013). Six and four plasma samples from blood donors 
with RT-PCR confirmed West Nile virus infection and ZIKV infection, respectively, 
were kindly provided by Dr. Michael Busch at the Blood Systems Research Institute 
at San Francisco. The study was approved by the IRB of the University of California, 
San Francisco.  
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RESULTS 
 
Specific Aim 1. Test if codon-optimized DNA vaccine expressing mature DENV 
VLPs induce better antibody responses than that expressing mixed VLPs. 
 
Experimental plan 
 
To test the immunogenicity of codon-optimized and non-codon optimized DNA 
vaccines expressing mature or immature DENV1 VLPs, four constructs were 
generated (Fig. 1). Expression and production of VLPs in vitro was first examined by 
WB analysis. Then 6-week-old female C57/BL6 mice were immunized im with 3 
doses of DNA vaccines expressing mature or mixed DENV1 VLPs. Sera were 
assayed for binding by ELISA and neutralization by foci reduction neutralization test 
(FRNT) using DENV1 (Crill, Hughes et al. 2012, Hughes, Crill et al. 2012). 
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Fig. 1. Schematic drawing of the pCB-based constructs pCBD1 and pCBD1-Fand 
human codon-optimized constructs pCBD1h and pCBD1hF. Wild type constructs 
contain genes for the prM and E proteins. Furin constructs contain gene for furin and 
IRES and flag in addition to prM and E genes. 
 
Expression of mature and mixed VLPs 
 
     Mature and immature VLPs were successfully produced by transfection of 
HEK293T cells with plasmid DNA constructs expressing the prM/E proteins of 
DENV1 in the presence or absence of furin (Fig.1). Expression and VLP production 
of DENV1 constructs were confirmed by WB analysis using anti-E mouse mAb to 
detect E proteins in cell lysates and VLP pellets derived from ultracentrifugation of 
culture supernatants of transfected cells (Fig. 2). E protein was expressed in all four 
constructs, with the codon-optimized furin construct (D1hF) showing higher 
expression than the non-optimized furin construct (D1F), and codon-optimized wild 
type construct (D1h) showing similar expression as the non-optimized wild type 
 53 
construct (D1). Expression in the codon-optimized wild type construct (D1h) was 
higher than that of the codon-optimized furin construct (D1hF). VLPs were generated 
by all four DENV1 constructs, with higher production in in the codon-optimized 
constructs for both furin and wild type compared to their non-optimized counterparts. 
In the codon-optimized constructs, VLP production was higher in the wild type than 
the furin. These results show that human codon-optimized constructs with furin 
increase the expression and production of VLPs greatly compared with non-
optimized constructs with furin.  
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Fig. 2. Western blot analysis to examine E protein expression in cell lysates and VLP 
production. (A) Long exposure and (B) Short exposure of gels of cell lysates and 
VLP production from HEK293T cells transfected with pCBD1, pCBD1F, pCBD1h, 
and pCBD1hF constructs probed with anti-E mouse mAb (1:200000) and calnexin 
(1:10000). 
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Binding and neutralization of immunized mice sera 
 
     Since codon-optimized constructs (pCBD1h and pCBD1hF) expressed better 
than non-codon-optimized constructs, these two constructs were chosen for 
immunization experiment. Groups of 7 female C57BL/6 mice were immunized with a 
three dose regimen of DNA vaccine of pCBD1h designated as D1-WT DDD or 
pCBD1hF designated as D1-F DDD (Fig. 3). Individual sera collected from 
vaccinated mice was first tested for binding and then for NT Abs to DENV1 virion 
(Fig. 4). Though not significantly different, the ELISA Ab titers in the D1-WT DDD 
group are higher than the D1-F DDD (Fig. 4A).  This is consistent with the higher 
expression levels of D1h than D1hF in vitro.  The NT50 titers for both D1-WT DDD 
and D1-F DDD groups were low (Fig. 4B).  
 
 
Fig. 3. Experimental protocol of mice immunization. Groups of 5 to 7 female 
C57BL/6 mice were immunized IM with 3 doses of DNA vaccines pCBD1h or 
pCBD1hF. Groups receiving virion-boost were immunized with 1 dose of DNA 
vaccines followed by two doses of inactivated virions by SC or IP route. Pooled and 
individual sera from each group were assayed for anti-DENV Abs and NT Abs.  
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Fig. 4. Titers of anti-DENV Abs and NT Abs of individual sera from mice vaccinated 
IM with three doses of DNA vaccine of pCBD1h or pCBD1hF. (A) Individual sera of 
pCBD1-WT and pCBD1-F immunized mice collected at 8 wk (n=7, each group) were 
subjected to DENV1 virion-ELISA. The endpoint titers were determined. (B) 
Individual sera of mice immunized with pCBD1-WT and pCBD1-F collected at 8 wk 
(n=7, each group) were subjected to FRNT and the FRNT50 titers were determined. 
 
Specific Aim 2. Test if DNA-prime and virion-boost strategy induces stronger 
antibody response than DNA alone. 
 
Experimental plan 
 
    To test the immunogenicity of DNA-prime and virion-boost, formalin- or H2O2-
inactivated mature and mixed DENV1 virions were generated by colleague in the lab 
(from Dr. Wen-Yang Tsai).  Then 6-week-old female C57BL/6 mice were immunized 
IM with 1 dose of DNA vaccines expressing mature or mixed DENV1 VLPs followed 
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by two doses of inactivated virion. Sera were assayed for binding by ELISA using 
mixed, mature (m), or immature (imm) DENV1 virions and neutralization by FRNT 
using mixed DENV1 virions (Crill, Hughes et al. 2012, Hughes, Crill et al. 2012).  
 
Binding and neutralization activity in mice sera after DNA-prime and virion-
boost immunization  
 
     Due to the low in vivo efficacy, a heterologous prime-boost regimen was 
implemented (Simmons, Porter et al. 2006, De Filette, Soehle et al. 2014). Mice 
were immunized with one dose of D1-WT DNA followed by two subcutaneous (SC) 
doses of formalin-inactivated mixed virion designated as D1-WT DVVsc, or one dose 
of D1-F DNA followed by two doses of formalin-inactivated mature virion designated 
as D1-F DVVsc.  Individual sera were tested on DENV1 virion-ELISA (Fig. 5A). The 
ELISA titer of the D1-WT DVVsc group was significantly higher than that of the D1-F 
DVVsc group (p=0.0262) demonstrating the induction of higher binding Abs by the 
WT group. Individual sera were also tested for neutralization (Fig. 5B). Although 
there was no significant difference between the two groups, they both showed higher 
neutralization compared with DNA immunization alone (D1-WT DDD and D1-F DDD 
groups, Fig. 4B). 
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Fig. 5. Titers of anti-DENV Abs and NT Abs of individual sera from mice immunized 
IM with one dose of DNA vaccine of pCBD1h or pCBD1hF followed by two SC doses 
of formalin-inactivated virions. (A) Individual sera of D1-WT DVVsc and D1-F DVVsc 
groups collected at 10 wk (n=7, each group) were subjected to DENV1 virion-ELISA. 
The endpoint titers were determined. (B) Individual sera of m D1-WT DVVsc and D1-
F DVVsc groups collected at 10 wk (n=7, each group) were subjected to FRNT and 
the FRNT50 titers were determined. 
 
 Pooled sera of the D1-WT DVV and D1-F DVV groups were also tested for 
binding to DENV1 virions from different cells or with different maturation status. 
When tested with vero cell-derived mixed DENV1 virions, the WT group showed 
ELISA titer that was greater than one log compared to the F group (Fig. 6A). The WT 
group also showed better binding to HEK293T-derived mixed and immature DENV1 
virions than the F group, but had similar ELISA titers when tested with the mature 
DENV1 virions (Fig. 6B). Taking the ratio of the ELISA titers of mature to immature 
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virions shows that the F group is much higher than the WT group (Fig. 6C). 
Consistent with this, the ratio of the NT50 over ELISA titers was higher in the F group 
than the WT group (P=0.0006, Fig. 6D), suggesting a better quality of Abs, based on 
higher binding to mature than immature virions and more potent NT activity, was 
induced by the F group compared with the WT group. 
 
 
Fig. 6. Titers of anti-DENV Abs and NT Abs of pooled sera from mice vaccinated IM 
with three doses of DNA vaccine of pCBD1h or pCBD1hF followed by two doses of 
inactivated virion. (A) Pooled sera of D1-WT DVVsc and D1-F DVVsc groups were 
subjected to vero-derived DENV1 virion-ELISA. The endpoint titers were determined. 
(B) Pooled sera of D1-WT DVVsc and D1-F DVVsc groups were subjected to 
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HEK293T-derived DENV1 mixed, immature, and mature virion-ELISAs. The endpoint 
titers were determined (C) Ratio of mature to immature DENV1 virion ELISA titers. 
(C) Ratio of NT50 to ELISA titers of D1-WT DVV to D1-F DVVm groups. 
 
  To test the immunogenicity of different routes of immunization, groups of 5 to 
7 female C57BL/6 mice were then immunized with one dose of D1-WT DNA followed 
by two intraperitoneal (ip) doses of formalin-inactivated mixed virion designated as 
D1-WT DVVip formalin, or one dose of D1-F DNA followed by two doses of formalin-
inactivated mature virion designated as D1-F DVVip formalin. Individual sera from 
the WT (Gr 11) and F (Gr 8+13) groups did not show a significant difference but both 
had high ELISA (Fig. 7A) and NT50 titers (Fig. 7B). There was no difference in the 
ELISA and NT Ab titers between ip and sc routes of immunization (Figs. 7C-D). 
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Fig. 7. Titers of anti-DENV Abs and NT Abs of individual sera from mice immunized 
IM with one dose of DNA vaccine of pCBD1h or pCBD1hF followed by two SC doses 
of formalin-inactivated virions. (A) Individual sera of D1-WT DVVip formalin (n=5) 
and D1-F DVVip formalin groups collected at 10 wk (n=7), were subjected DENV1 
virion-ELISA. The endpoint titers were determined. (B) Individual sera of m D1-WT 
DVVip formalin (n=5) and D1-F DVVip formalin (n=7) groups collected at 10 wk were 
subjected to FRNT and the FRNT50 titers were determined. (C) Comparison of 
ELISA titers between ip and sc routes of immunization in WT and F groups. (D) 
Comparison of NT50 titers between ip and sc routes of immunization in WT and F 
groups. 
 
To test the immunogenicity of hydrogen peroxide (H2O2) inactivation, female 
C57BL/6 mice were immunized with one dose of D1-WT DNA followed by two ip 
doses of H2O2-inactivated mixed virions designated as D1-WT DVVip H2O2, or one 
dose of D1-F DNA followed by two doses of H2O2-inactivated mature virions 
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designated as D1-F DVVip H2O2. Both groups showed high ELISA titers (Fig. 8A). 
The F group (Gr12) showed slightly higher NT50 titers, though not significant, 
compared with the WT group (Gr 14+15); both had moderate neutralization activity 
(Fig. 8B). There was no difference in ELISA Ab titers between formalin and H2O2 
inactivation (Fig. 8C). However, a higher NT Ab titer in the D1-WT DVVip formalin 
group was seen compared to its H2O2 counterpart.  
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Fig. 8. Titers of anti-DENV Abs and NT Abs of individual sera from mice immunized 
IM with one dose of DNA vaccine of pCBD1h or pCBD1hF followed by two SC doses 
of formalin-inactivated virions. (A) Individual sera of D1-WT DVVip H2O2 (n=5) and 
D1-F DVVip H2O2 (n=7) groups collected at 10 wk were subjected DENV1 virion-
ELISA. The endpoint titers were determined. (B) Individual sera of D1-WT DVVip 
H2O2 (n=5) and D1-F DVVip H2O2 (n=7) were collected at 10 wk were subjected to 
FRNT and the FRNT50 titers were determined. (C) Comparison of ELISA titers 
between H2O2 and formalin inactivation in WT and F groups. (D) Comparison of 
H2O2 and formalin inactivation in WT and F groups. 
 
Specific Aim 3. To develop and validate a serological test to distinguish DENV 
and ZIKV. 
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Experimental plan 
 
To develop ELISA based on NS1 protein, recombinant NS1 (rNS1) proteins 
were generated for ZIKV, DENV1-2, WNV, and YFV. Then RT-PCR confirmed sera 
of patients with primary ZIKV (pZIKV), ZIKV infection with previous DENV 
(ZIKVwpDENV) and secondary DENV (sDENV) infections were assayed by IgG and 
IgM ELISA using rNS1 protein (Steinhagen, Probst et al. 2016). 
 
E-based IgG ELISAs 
 
Panels of serum or plasma samples from patients with primary DENV1 (pDENV1), 
primary WNV (pWNV), pZIKV, sDENV and ZIKVwpDENV infections were first tested 
with traditional E protein-based IgG ELISAs, including ZIKV-VLP, DENV1-inactivated 
virion (IV), and WNV-VLP IgG ELISAs. The ZIKV-VLP, DENV1-IV, and WNV-VLP 
ELISAs showed cross-reactivity across all serum and plasma samples. The ZIKV-
VLP ELISA (Fig. 9A) showed positive for 5 out of 6 (83%) in pWNV, 16 out of 16 
(100%) in pDENV1, 4 out of 4 (100%) in pZIKV, 22 out of 22 (100%) in sDENV, and 
8 out of 8 (100%) in ZIKVwpDENV groups. Similarly, the DENV1-IV ELISA (Fig. 9B) 
showed positive for 5 out of 6 (83%) in pWNV, 16 out of 16 in pDENV1, 4 out of 4 in 
pZIKV, 22 out of 22 in sDENV, and 8 out of 8 in ZIKVwpDENVgroups. The WNV-
VLP ELISA (Fig. 9C) showed positive for 6 out of 6 in pWNV, 16 out of 16 in 
pDENV1, 3 out of 4 (75%) in pZIKV, 22 out of 22 in sDENV, and 8 out of 8 in 
ZIKVwpDENV groups. Thus, the E-based IgG ELISAs are not able to distinguish 
between pWNV, pDENV1, pZIKV, sDENV, and ZIKVwpDENV infections. 
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Fig. 9. Results of ZIKV-VLP, DENV1-IV, and WNV-VLP IgG ELISAs for pDENV, 
pZIKV, pWNV, sDENV, and ZIKVwpDENV panels. (A) ZIKV-VLP, (B) DENV1-IV, 
and (C) WNV-VLP IgG ELISAs in convalescent-phase samples from pDENV, pZIKV, 
pWNV, sDENV, and ZIKVwpDENV panels. 
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Expression and purification of rNS1 proteins 
 
To produce rNS1 proteins of ZIKV, DENV1, DENV2, WNV, and YFV, five pMT-bip 
constructs were generated first (Fig. 10A). Stable clones were then established in 
Drosophila S2 insect cells and confirmed by Western blot analysis using anti-His Ab 
(Fig. 10B) and coomassie blue staining (Fig. 10C). The ZIKV-NS1 stable clones 
were most notably able to show the presence of the NS1 monomer and dimer. The 
supernatants were run through a His-trap column in a fast purification 
chromatography system to obtain pure NS1 protein. Coomassie blue staining shows 
purified ZIKV-NS1 protein in monomer and dimer forms (Fig. 10D), as well as 
monomers of the WNV, D1, D2, and YFV-NS1 proteins (Fig. 10E). 
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Fig. 10. (A) Schematic drawing of the pMT-based constructs. All constructs contain 
the N-terminal signal sequence from the insect Bip gene and a His-tag at the C-
terminus. (B) Western blot analysis using anti-His Ab and (C) coomassie blue 
stained gel of ZIKV-NS1 stable clones. Purified NS1 proteins of (D) ZIKV, (E) WNV, 
YFV, DENV1, and DENV2. 
 
NS1 IgG ELISAs for pDENV1, pWNV, and pZIKV infections 
 
Panel of sera and plasma from patients with pDENV1, pWNV, and pZIKV infections 
were tested on ZIKV- (Fig. 11A), DENV1- (Fig. 11B), and WNV-NS1 IgG ELISAs 
(Fig. 11C). The ZIKV-NS1 ELISA showed no cross-reactivity with the pWNV (0 out of 
6) and pDENV1 (0 out of 16) samples, while 3 out of 4 pZIKV samples were positive. 
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There was also no cross-reactivity seen on the DENV1-NS1 ELISA with pWNV and 
pZIKV samples while 13 out of 16 pDENV1 samples were positive. The WNV-NS1 
ELISA was positive for 5 out of 6 (83%) of the pWNV samples and showed no cross-
reactivity with pDENV1 and pZIKV samples (Table 1). Taken together, the NS1 IgG 
ELISA for primary infection panels had a sensitivity of 75% for ZIKV-NS1, 81.5% for 
DENV-NS1, and 83.3% for WNV-NS1 and 100% specificity for all three (Table 2). 
Thus, our ELISAs are able to distinguish between pDENV, pZIKV, and pWNV 
infections with high sensitivity and specificity.  
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Fig. 11. Results of ZIKV-NS1, DENV1-NS1, and WNV-NS1 IgG ELISAs for pDENV, 
pZIKV, and pWNV panels. (A) ZIKV-NS1, (B) DENV1-NS1, and (C) WNV-NS1 IgG 
ELISAs in convalescent-phase samples from pDENV, pZIKV, and pWNV panels.  
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.  
Table 1. Positive rates of DENV1-, and ZIKV-, and WNV-NS1 IgG ELISAs in 
pDENV1, pZIKV, and pWNV panels.   
 
 
Table 2. Sensitivity and specificity DENV1-, and ZIKV-, and WNV-NS1 IgG ELISAs 
in pDENV1, pZIKV, and pWNV panels. 
 
NS1 IgG ELISAs for sDENV, and ZIKVwpDENV infections 
 
Previous studies have been able to show good sensitivity and specificity for 
serological tests on primary infection samples (Steinhagen, Probst et al. 2016) but 
have been able to clearly demonstrate the same results for patients who may have a 
secondary infection. Panel of serum and plasma samples from patients with sDENV 
and ZIKVwpDENV infections were tested on DENV1-NS1 and ZIKV-NS1 ELISAs. 
The sDENV samples were positive on the DENV-NS1 ELISA. ZIKVwpDENV 
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samples including 20 from Nicaragua and 19 from Brazil were positive on both 
DENV1- and ZIKV-NS1 ELISAs (Figs. 12A and 12B). Although there was some 
cross-reactivity of the sDENV samples on the ZIKV-NS1 ELISA, it was mostly able to 
distinguish between sDENV and ZIKVwpDENV (Fig. 12B). In order to further 
distinguish between sDENV and ZIKVwpDENV, the ratio of ZIKV-NS1 over DENV1-
NS1 relative OD was taken with a cutoff value of 0.24 (Fig. 12C). The results of this 
show that the addition of the DENV1-NS1 ELISA can distinguish ZIKVwpDENV and 
sDENV infections. This was able to improve the sensitivity of the assay to 87.5% and 
the specificity to 81.3%.  
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Fig. 12. Results of ZIKV-NS1 and DENV1-NS1 IgG ELISAs for sDENV and 
ZIKVwpDENV panels. (A) DENV1-NS1 and (B) ZIKV-NS1 IgG ELISAs in 
convalescent-phase samples from sDENV, ZIKVwpDENV (Nicaragua [Nic]) and 
probable ZIKVwpDENV (Brazil [Bra]) panels. (C) rOD ratio of ZIKV-NS1 to DENV1-
NS1. The sensitivity and specificity are shown based on a cut-off rOD ratio at 0.24. 
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(D) DENV1-NS1 and (E) ZIKV-NS1 IgG ELISAs in post-convalescent-phase samples 
(3 months to 2 years POS) from sDENV panels. (F) Positive rates of DENV1- and 
ZIKV-NS1 IgG ELISAs in sDENV panels over time.  Dotted lines indicate cut-off rOD 
values for ELISAs. Data are mean of two experiments (each in duplicates). Two-
tailed Mann-Whitney test was used to compare two groups. 
 
Cross-reactivity of sDENV panel to ZIKV-NS1 protein over time 
 
To investigate whether the cross-reactivity of sDENV samples to ZIKV-NS1 is limited 
to the convalescent phase, 38 post-convalescent phase samples of sDENV cases 
ranging from 3 months to 2 years post infection were tested. Because the post-
convalescent phase samples were collected at different time points, they were 
separated into different time ranges to determine if this affects the positivity rates. 
The rOD values for both DENV1-NS1 (Fig. 12D) and ZIKV-NS1 IgG ELISA (Fig. 
12E) in these samples did not show a significant difference from those in the 
convalescent-phase samples. A decrease in the positivity rates of the sDENV panels 
in the ZIKV-NS1 IgG ELISA was observed, from 83.3% (3 to 6 months POS) to 
27.7% (1 year POS) and 28.6% (1.5 to 2 years POS) (Fig. 12F).  
 
Proposed algorithm to distinguish ZIKV and DENV infections 
 
Based on the results of three ELISAs, the ZIKV-NS1 IgM, ZIKV-NS1 IgG and DENV-
NS1 IgG ELISAs (as summarized in Tables 3, 4 and 5), we propose an algorithm to 
distinguish pZIKV, ZIKVwpDENV, and sDENV infections in dengue and Zika 
endemic regions, especially where they geographically overlap (Fig. 13). 
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Fig. 13. Proposed algorithm of using three serological tests (without neutralization 
tests) to distinguish pZIKV, ZIKVwpDENV, pDENV, and sDENV infections in dengue 
and Zika endemic regions in the framework of CDC guidelines for laboratory 
diagnosis of ZIKV infection. *specificity=95%; **specificity=90.9%; 
***sensitivity=87.5%, specificity=81.3% based on Figure 11 and Table 4. 
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Table 3. Results of ZIKV-NS1 IgM, ZIKV-NS1 IgG, and DENV1-NS1 IgG ELISAs in 
different serum and plasma panels. Abbreviations: naïve, flavivirus-naïve; pDENV1, 
primary DENV1 infection; pZIKV, primary ZIKV infection; sDENV: secondary DENV 
infection; ZIKVwpDENV, ZIKV infection with previous DENV infection; ELISA, 
enzyme-linked immunosorbent assay; Nic, Nicaragua. aResults were based on data 
from two experiments (each in duplicates) as described in Methods. bFor pDENV1 
panel, only those collected within 3 months post-onset of symptoms were tested for 
IgM. 
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Table 4. Numbers of positive and negative for ZIKV-NS1 IgM, ZIKV-NS1 IgG, and 
DENV1-NS1 IgG ELISAs and their combinations. Abbreviations: naïve, flavivirus-
naïve; pDENV1, primary DENV1 infection; pZIKV, primary ZIKV infection; sDENV: 
secondary DENV infection; ZIKVwpDENV, ZIKV infection with previous DENV 
infection; ELISA, enzyme-linked immunosorbent assay; Nic, Nicaragua. aResults 
were based on data from two experiments (each in duplicates) as described in 
Methods. bFor pDENV1 samples, only those collected within 3 months post-onset of 
symptoms were tested for IgM. 
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Table 5. Sensitivity and specificity of three NS1 ELISAs and their combinations. 
Abbreviations: pZIKV, primary ZIKV infection; sDENV: secondary DENV infection; 
ZIKVwpDENV, ZIKV infection with previous DENV infection; ELISA, enzyme-linked 
immunosorbent assay. aZIKV includes pZIKV and ZIKVwpDENV infections. DENV 
includes primary DENV1 and sDENV infections. bData were based on Table 3 and 
Table 4. Data from flavivirus-naïve samples were not included in the analysis. 
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Overview 
 
     In this study, we first investigated the immunogenicity of human codon-optimized 
DNA vaccines expressing mature and mixed DENV particles by examining the 
characteristics of the Abs produced by immunized mice. We then tested a DNA-
prime and virion-boost strategy to examine the Ab response and compare it to the 
Ab response of DNA alone. Finally, we aimed to develop a serological assay to 
distinguish DENV and ZIKV infections, which is critical to further our understanding 
of ZIKV pathogenesis and complications during pregnancy. 
     WB results from expression and VLP production of our D1 constructs (Figs. 1A-B) 
show that human codon-optimized constructs with furin increase the expression and 
production of VLPs greatly compared with non-optimized constructs with furin, 
whereas a mild increase is found in constructs without furin. This supports our 
hypothesis that human codon-optimized DNA constructs can improve the expression 
of VLPs as a better candidate vaccine for DENV.  
To explore the immunogenicity of mature virions in vivo, we immunized one 
group of female C57BL/6 mice with pCBD1-WT or pCBD1-F, which express mixed or 
mature VLPs, respectively. Sera collected from the mice groups were subjected to 
ELISA and FRNT assays. Results of total anti-DENV Abs based on 3-layer ELISA 
and FRNT50 titers are generally in agreement with the expression and VLP 
production of these D1 constructs based on WB analysis, in which there was a 
higher expression level of D1h than D1hF in vitro (Figs. 1A-B, Figs. 4A-B). Mice were 
able to produce anti-DENV Abs with similar titers induced by both DNA vaccines, 
suggesting that the vaccine producing mature VLPs (pCBD1-furin) is immunogenic 
compared with pCBD1-WT (Fig. 4A). Some variation in titers among individual mice 
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was observed (Fig. 4A), which could be due the technique of handling and vaccine 
administration. Both DNA vaccines induced low FRNT50 titers (Fig. 4B). This may be 
due to the low immunogenicity of DNA vaccine compared with others and lack of or 
low in vivo efficacy that have been reported (Danko, Beckett et al. 2011, De Filette, 
Soehle et al. 2014). 
     As an approach to improve the efficacy of our DNA vaccine in vivo, we applied a 
DNA-prime and virion-boost immunization strategy. Introducing a virion-boost using 
formalin-inactivated D1 virions administered subcutaneously showed that mice were 
able to produce anti-DENV Abs with similar titers when compared to the DNA only 
groups, with the D1-WT DVVsc formalin group showing a higher ELISA titer than the 
D1-F DVVsc formalin group (Fig. 5A). FRNT50 titers in these two groups were both 
higher than those of the DNA only groups but did not show difference between each 
other (Fig. 5B). In order to determine which route of administration would result in 
better titers, ip immunization of formalin-inactivated DENV1 virion was also tested. 
Although both routes of immunization showed high ELISA and FRNT50 titers, there 
was no significant difference in the ELISA and FRNT50 titers between the ip and sc 
routes of immunization (Fig. 7C-D), suggesting that both routes are effective in 
eliciting neutralizing Abs. Because the ip route showed slightly higher FRNT50 titers, 
we continued to use this route for our future immunization groups. In addition to 
vaccine delivery routes, we also tested H2O2 as another method of virion inactivation. 
Although formalin is the more common method for inactivation, recent studies have 
shown that using H2O2 is promising (Amanna, Raue et al. 2012, Walker, Raue et al. 
2012, Pinto, Richner et al. 2013). H2O2-inactivated WT and F groups showed higher 
ELISA (Fig. 8A) FRNT50 titers (Fig. 8B) than the DNA-only groups. There was no 
significant difference between using formalin or H2O2 inactivation in the ELISA titer 
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(Fig. 8C). A higher NT50 titer in the D1-WT DVVip formalin group than the H2O2 group 
was seen (Fig. 8D), suggesting that formalin-inactivation may be more effective. 
We further tested the titers of binding Abs from pooled sera to DENV from the 
DVV WT and F groups to mixed, immature, and mature DENV1 virions. As expected, 
the WT group was able to show higher ELISA titers than the F group when tested 
with vero DENV1 mixed virions and 293T DENV1 mixed and immature virions (Figs. 
6A and 6B). When tested with DENV1 mature particles, the ELISA titers were lower 
compared with those to the mixed and immature DENV1 virions (for both the WT and 
F groups) (Fig. 6B), suggesting that the mature particles were less recognized by the 
Abs. Comparing the ELISA titers to immature DENV1 between the WT and F groups, 
there was more than 1 log difference, whereas comparing the ELISA titers to mature 
DENV1 between the WT and F groups, there was less than 0.5 log difference.  In 
order to better compare the binding of Abs to mature and immature DENV1, we 
looked at the ratio of ELISA titer to mature to that of immature particles. The ratio 
was lower in the WT group, suggesting that they are able to better differentiate 
between the mature and immature particles. 
Due to the recent ZIKV outbreak in DENV endemic areas, a serological 
diagnostic assay to differentiate the two has become increasingly important. We 
used ZIKV-VLP, DENV1-IV, and WNV-VLP IgG ELISAs to show that E-protein 
based ELISAs are unable to differentiate between pWNV, pDENV1, pZIKV, sDENV, 
and ZIKVwpDENV infections (Fig. 9). Our results demonstrate that our NS1 IgG 
ELISA is able to differentiate between pDENV, pZIKV, and pWNV convalescent 
samples (Fig. 11, Tables 1-2). We needed to further address secondary infections 
due to the geographic co-circulation of dengue and Zika. The cross-reactivity seen in 
the ZIKVwpDENV panel on the DENV1-IgG ELISA suggests that a single test is not 
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enough to accurately diagnose the infection (Fig. 12A). An additional assay using a 
ZIKV-NS1 ELISA was developed to test sDENV and ZIKVwpDENV panels (Fig. 
12B). Using both the DENV1 and ZIKV-NS1 ELISAs in combination is able to 
differentiate sDENV and ZIKVwpDENV infections, and using the rOD ratio based on 
the two ELISAs with a cutoff of 0.24 is able to further separate this distinction (Fig. 
12C). These results demonstrate a simple and relatively quick way to diagnose these 
two infections. Currently, using our proposal of three serological tests to distinguish 
pZIKV, ZIKVwpDENV, and sDENV infections is a novel method. The algorithm of 
using these three ELISAs can be applied to clinical diagnoses of these infections 
(Fig. 13). This is particularly relevant for pregnant women both residing and returning 
from dengue endemic regions, most of whom present with asymptomatic infection or 
might miss the golden period of detection by RT-PCR, good serological tests can 
help us to better understand and treat the ZIKV related complications during 
pregnancy. Because the algorithm calls for ELISAs, the testing can bypass the time 
that is needed to do PRNTs in the current CDC guidelines, thus improving the cost 
and time-efficiency. 
 
 Limitations and future plans 
 
 There are several limitations of this study. In Aim 1, one main limitation was the 
sample size of our mice. Also, there may have been variations in the amount DNA 
vaccine delivered and sera collected due to the handling of the mice. As this was the 
initial study conducted, there may be some differences in the quality of techniques 
compared to later mouse studies. Further studies using a larger number of mice is 
required.  
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     There were also limitations in Aim 2. This study was conducted to look at the 
binding and neutralizing anti-DENV1 Abs. Further studies looking at T-cell 
responses, ADE, percent anti-FL Abs, anti-pr, and anti-E Abs should be done. 
Moreover, challenge experiments in AG129 mice model to test the protective efficacy 
of these vaccines or passive transfer experiments in AG129 mice are needed for 
vaccine development.  These are the ongoing collaborative research with our 
collaborators at CDC Fort Collins. For this aim, we only looked at using inactivated 
virions as a form of protein-boost. For future experiments, recombinant E proteins 
can be generated to use in vaccinations.  
 For Aim 3, one limitation is that the sample size is small and future studies would 
require larger sample sizes to further validate the observations. Also, future studies 
using sequential samples from various time-points after different flaviviral infections 
are needed to further extend this approach and validate the assays. Finally, our 
assays used only the DENV1 serotype and ZIKV-NS1. Future studies should include 
the other DENV serotypes both individually and as a mixture, as well as other 
relevant flaviviruses such as JEV, YFV, WNV, and TBEV to further distinguish these 
from ZIKV. 
 
Concluding summary 
 
     In summary, our study showed that human-codon optimized constructs increased 
the expression and production of VLPs. Using human codon-optimized DNA 
vaccines to test our hypothesis, we showed that DNA vaccine expressing mature 
VLPs can induce similar anti-DENV Abs and NT Abs compared with DNA vaccine 
expressing mixed VLPs. Using a DNA-prime and inactivated virion-boost regimen, 
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we showed improved ELISA and NT titers compared to DNA alone through different 
delivery and virion inactivation methods. Our study also showed that an algorithm 
using three ELISAs are a cost- and time-effective way to accurately differentiate 
ZIKV and DENV infections. Together, these three aims provide new strategies in 
dengue vaccine development to prevent DENV infection and the new methods for 
serodiagnosis of flaviviruses in endemic regions.        
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